RemeGen Co (HKSE:09995) Days Sales Outstanding : 0.00 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Days Sales Outstanding?

RemeGen Co's average Accounts Receivable for the three months ended in Dec. 2023 was HK$325.6 Mil. RemeGen Co's Revenue for the three months ended in Dec. 2023 was HK$0.0 Mil.

The historical rank and industry rank for RemeGen Co's Days Sales Outstanding or its related term are showing as below:

HKSE:09995' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.59 Med: 48.63 Max: 118.97
Current: 118.97

During the past 6 years, RemeGen Co's highest Days Sales Outstanding was 118.97. The lowest was 0.59. And the median was 48.63.

HKSE:09995's Days Sales Outstanding is ranked worse than
73.04% of 894 companies
in the Biotechnology industry
Industry Median: 72.38 vs HKSE:09995: 118.97

RemeGen Co's Days Sales Outstanding declined from Sep. 2022 (42.71) to Dec. 2023 (0.00).

RemeGen Co Days Sales Outstanding Historical Data

The historical data trend for RemeGen Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Days Sales Outstanding Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

0.59

48.63

85.46

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial									93.04	-	40.62	-	82.77

Competitive Comparison of RemeGen Co's Days Sales Outstanding

For the Biotechnology subindustry, RemeGen Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Days Sales Outstanding falls into.

RemeGen Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

RemeGen Co's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (225.611	+	325.594)	/	2 )	/	1177.048	*	365
=	275.6025					/	1177.048	*	365
=	85.46

RemeGen Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	325.594)	/	1 )	/	0	*	365 / 4
=	325.594					/	0	*	365 / 4
=	N/A

RemeGen Co (HKSE:09995) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

RemeGen Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines